Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
about
The History of Clotting Factor Concentrates PharmacokineticsPharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.Treatment of hemophilia B: focus on recombinant factor IX.Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.A global view on prophylaxis: possibilities and consequences.Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.The pharmacokinetics of clotting factor therapy.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Haemophilia B: Christmas disease.Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.Pediatric Dosing and Body Size in Biotherapeutics.Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.Haemophilia B: current pharmacotherapy and future directions.Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.The role of Rixubis™ in the treatment of hemophilia B.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.Emerging drugs for the treatment of hemophilia A and B.Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?A study of reported factor IX use around the world.Prophylaxis in factor IX deficiency product and patient variation.A bodyweight-dependent allometric exponent model for scaling clearance of clotting factor VIII and IX from infants to adults.Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Individualized factor IX dosing in two brothers: application of longitudinal pharmacokinetic modelling to optimize therapeutic benefit.Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B.The features of clearance in recombinant factor IX (BeneFIX(®) ).Efficacy and safety of OCTANINE F in children with haemophilia B.Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
P2860
Q30235127-482AB4C8-548B-4370-A7EF-66C308F41433Q30685072-3B966098-41F9-4EFA-BDB5-8F2DA7D56794Q34329068-A35D9C1A-BE6D-44F7-9630-FA0F9FD407F1Q34492760-464210A3-E894-4A8E-A33F-19BF1E26CE94Q35112430-DEA7F4F6-240E-4372-AFC3-2F4F1B00FB2EQ35112459-35E87179-7F9B-426F-91EC-4C48290A78CBQ35163599-99AE2712-DBB6-441B-8974-11B1F349F3B9Q35692016-C06B93E6-BFE9-4586-BBC8-AF4F5C580930Q36221979-07FC51A6-6C29-447D-898E-AD30C5ED3E27Q36291059-E29DF3D5-4100-472A-ADB0-52243EA4E413Q36480548-6A9B742F-E2A2-4881-80AF-FD558F79A8A5Q37591452-A45E1381-938D-47E3-A2CF-60ECAD7C1DE9Q37634856-D19A350D-7F6E-4495-AC61-9D845E3C38E4Q37666711-D6445FD0-7BB3-45CD-98D1-7C3E13716C13Q38011809-710A518E-87E0-4880-BF33-9805CF5A7EE4Q38040458-B2E952D0-442B-48AA-AF94-C1F7C6404971Q38115812-6428D6F4-D281-42C4-A25F-CD0ACC6F1B82Q38127745-22287C86-2F0F-412A-9DC7-DD8F2868A229Q38210808-6E9C437D-0F55-4E22-9611-0C41DFA6E871Q38237476-D0883FEE-7997-4587-9E4D-5CAE5EF86BCCQ38238972-1779526E-8CD4-4AC0-A766-9FCCFBC2C1B0Q38933707-8667E05A-30E6-410F-8E5A-BE8FC82E11DAQ38935228-723836C5-91AA-46D4-B9DA-552EF3B627C2Q39499567-42A1596A-C0EE-4A23-ABF2-A7E548460369Q40066317-73800A37-4B74-4E37-A980-1570F7E560FCQ43962143-B76EE638-CA59-432A-99C8-956F1ACF1D55Q44859791-9C18D494-AC46-421D-86D2-1C3306AFF5EBQ45861566-40A764D0-559A-466F-BD29-0F5AAC1FC108Q45862027-1C85DB54-A33C-482E-BD3B-06018CF9B8DFQ45864037-93220601-27FF-4402-A459-D6EBF517992CQ45864852-432D12D2-DAA0-4E77-8740-93E092A80F98Q45866870-588A93CF-7DBC-4249-8E53-BF76FBF0039AQ45869569-2842D2C7-6070-4B74-B7EF-4AAB64FED1D8Q45870386-F3E382AB-9B67-45A1-9427-AB6F6C0ABADCQ45871094-71999E5A-1FFA-4939-BBFD-317D4303B8B1Q45872780-943DE874-3C8D-49BC-9F0F-FAF29290CD11Q45874776-D4F34F94-7144-4950-84F2-1739163F0387Q45876094-9A32E19E-F3A7-4A0F-84D3-25B76B60F724Q45876681-91909C49-9AF4-434B-A7C6-F9E52CF8A2CEQ45879737-5D21407C-4C88-4A5F-96D1-A41A4DD751C7
P2860
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@en
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@nl
type
label
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@en
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@nl
prefLabel
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@en
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetics of recombinan ...... ons for dosing in prophylaxis.
@en
P2093
Berntorp E
Björkman S
Shapiro AD
P2860
P304
P356
10.1046/J.1365-2516.2001.00465.X
P577
2001-03-01T00:00:00Z